PDF
ePub
Citation
Print
Abstract
This review highlights articles pertaining to the following 5 topics: the relationship between asthma, allergic and non-allergic rhinitis; the novel asthma phenotypes using cluster analysis; the diagnostic properties of inhaled dry-powder mannitol for the diagnosis of asthma; the value of mepolizumab therapy in exacerbations of refractory eosinophilic asthma; the role of bronchial thermoplasty in the treatment of severe asthma.
Figures and Tables
Figure 1
Reduction of the original 628 variables in the SARP database. The 17 composite variables from the questionnaire data incorporate answers from 63 individual questions. The 34 final variables in the cluster analysis include 23 variables from the questionnaire data, 6 related to lung function and 5 markers of atopy. Following the cluster analysis, stepwise discriminant analysis identified 11 significant predictors of cluster assignment. Three of these variables (Baseline and Maximal FEV1 % predicted, age of disease onset) were used in the Tree analysis.
Figure 2
Tree analysis. Using three variables (baseline FEV1 [with a bronchodilator withhold], maximal "Max" FEV1 after six to eight puffs of albuterol, and age of onset of asthma), subjects can be assigned to the five clusters that range from milder asthma (Cluster 1) to more severe disease (Clusters 4 and 5).
Figure 3
Severe exacerbations during the course of the study. (A) shows the cumulative number of severe exacerbations that occurred in each study group over the course of 50 weeks. (B) shows the distribution of the number of exacerbations among subjects in each study group during the treatment period of the study. The mean number of exacerbations per subject over the course of the 50-week treatment period was 2.0 in the mepolizumab group, as compared with 3.4 in the placebo group (relative risk, 0.57; 95% confidence interval, 0.32 to 0.92; p=0.02).
Figure 4
Change in asthma quality of life by treatment group. (A) Change in AQLQ score over 12 months after treatment with BT (diamonds) or sham control (squares) in the per protocol population. (B) Percentage of subjects achieving an AQLQ score change of 0.5 or greater (the minimal important difference), -0.05 to less than 0.5, and 20.5 after treatment with BT (black) or sham control (white) in the per protocol population. *Posterior probability of superiority 5 97.9%, †Posterior probability of superiority 5 100.0% for "Net" benefit ([proportion improving-proportion deteriorating in the BT group]-[proportion improving-proportion deteriorating in the sham group]). BT: bronchial thermoplasty; AQL: asthma quality of life questionnaire.
Figure 5
Healthcare utilization events during the post-treatment period. Severe exacerbations (exacerbation requiring treatment with systemic corticosteroids or doubling of the inhaled corticosteroids dose), emergency department visits, and hospitalizations occurring in the post-treatment period. Open bars, sham; shaded bars, bronchial thermoplasty. All values are means 6 SEM. *Posterior probability of superiority 5 95.5%, †Posterior probability of superiority 5 99.9%.
References
1. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008. 372:1049–1057.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001. 108:S147–S334.
3. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002. 109:419–425.
4. Plaschke PP, Janson C, Norrman E, Björnsson E, Ellbjär S, Järvholm B. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am J Respir Crit Care Med. 2000. 162:920–924.
5. Leynaert B, Neukirch C, Kony S, Guénégou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004. 113:86–93.
6. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010. 181:315–323.
7. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007. 119:405–413.
8. Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study. J Allergy Clin Immunol. 2009. 124:928–932.
9. Brusasco V, Crimi E. Methacholine provocation test for diagnosis of allergic respiratory diseases. Allergy. 2001. 56:1114–1120.
10. de Meer G, Marks GB, Postma DS. Direct or indirect stimuli for bronchial challenge testing: what is the relevance for asthma epidemiology? Clin Exp Allergy. 2004. 34:9–16.
11. Anderson SD. Provocative challenges to help diagnose and monitor asthma: exercise, methacholine, adenosine, and mannitol. Curr Opin Pulm Med. 2008. 14:39–45.
12. Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin Exp Allergy. 2008. 38:43–50.
13. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009. 360:973–984.
14. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000. 161:64–72.
15. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005. 115:720–727.
16. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002. 360:1715–1721.
17. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemière C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006. 27:483–494.
18. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009. 360:985–993.
19. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010. 181:116–124.
20. Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J. 2004. 24:659–663.
21. Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol. 2004. 97:1946–1953.
22. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007. 176:1185–1191.
XML Download